PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

NEWSLETTER: New blood test matches gold standard for liver disease diagnosis

A new AI-powered blood test called LiquidTransformer matches the accuracy of magnetic resonance elastography in staging MASH and identifying treatment candidates, according to data presented at The Liver Meeting.

9sources
9articles
7velocity
+141%since first seen
11d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

An experimental blood test named LiquidTransformer, developed by Hepta, demonstrated diagnostic accuracy comparable to magnetic resonance elastography (MRE) for staging metabolic dysfunction-associated steatohepatitis (MASH) and identifying patients eligible for Rezdiffra, the first approved MASH therapy. The findings were presented in six separate studies at The Liver Meeting, the annual gathering of the American Association for the Study of Liver Diseases, held in Denver. Dr. Rohit Loomba of UC San Diego, Hepta's chief medical and scientific adviser, said MRE has been the non-invasive benchmark for staging liver fibrosis without biopsy, and seeing a blood test approach its accuracy is a real step forward given the wider availability of blood tests. The test analyzes DNA circulating in routine blood samples using AI to determine liver biology. In collaboration with Hepta and Madrigal Pharmaceuticals, researchers showed LiquidTransformer accurately staged liver damage and identified treatment-eligible patients. The technology also distinguished between three forms of steatotic liver disease: MASLD driven by metabolic dysfunction, ALD driven by alcohol, and MetALD where both coexist. In patients receiving semaglutide, the test detected molecular changes attributable to the GLP-1 drug, which is approved in the US to treat MASH. LiquidTransformer was reported to be nearly as accurate as MRE and more accurate than second-line alternatives such as vibration-controlled transient elastography and the enhanced liver fibrosis test. Separately, the LITMUS prospective multicentre diagnostic accuracy study published in The Lancet confirmed that while single non-invasive markers like FIB-4 and APRI show limited performance against histology for detecting at-risk MASH, multimarker proteomic panels show strong diagnostic performance. The Clinical Trial Vanguard reported that biopsy-gated enrollment in MASH trials is institutional inertia, not scientific preference, and that LITMUS-validated proteomic panels could reduce screen failure rates dramatically. The FDA accepted a Letter of Intent in August 2025 to qualify liver stiffness measurement by vibration-controlled transient elastography as a reasonably likely surrogate endpoint for non-cirrhotic MASH trials, but this covers only one imaging modality, not proteomic panels. The Global Liver Institute convened a Beyond the Biopsy National Implementation Forum in Denver on November 4, bringing together patients, clinicians, researchers, and industry to address barriers to non-invasive liver assessment. Holden said earlier identification of liver disease must become a consistent part of liver health, not an opportunity dependent on where a patient receives care. Dr. Brent A. Tetri, who moderated the forum, said primary care providers and endocrinologists need practical tools to assess liver health and determine when further evaluation is needed. GENFIT CEO Pascal Prigent emphasized that as treatment options expand, patients need practical, non-invasive ways to be properly diagnosed and monitor disease and treatment response. GLI will develop a draft National Implementation Roadmap outlining barriers, proposed actions, and milestones for equitable access.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 8d ago.

Quick answers

What is LiquidTransformer and how does it work?

LiquidTransformer is an experimental blood test from Hepta that uses AI to analyze DNA circulating in routine blood samples to determine liver biology, staging MASH and identifying treatment-eligible patients with accuracy comparable to magnetic resonance elastography.

How does LiquidTransformer compare to current diagnostic methods for MASH?

In six presentations at The Liver Meeting, LiquidTransformer was reported to be nearly as accurate as MRE, the most accurate non-invasive method, and more accurate than second-line alternatives like vibration-controlled transient elastography and the enhanced liver fibrosis test.

What are the implications for MASH clinical trials and patient care?

The LITMUS study published in The Lancet shows multimarker proteomic panels can replace biopsy for trial eligibility, potentially reducing screen failure rates. The Global Liver Institute is developing a National Implementation Roadmap to bring non-invasive testing into primary care and endocrinology settings for earlier identification of at-risk patients.

Coverage (9)

Topics

Related trends

◼ Archived Health 🔮 fades ✓

Molecular mechanisms and pathogenesis of MASH

Researchers have identified five biologically distinct subtypes of Metabolic Dysfunction-Associated Steatohepatitis (MASH), suggesting a need for personalized care.

7 sources 7 articles v 5 70d ago
\n \n \n \n \n \n \n